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Summary
Background: Diabetes mellitus promotes atrial structural remodeling, thereby producing atrial
arrhythmogenicity, where advanced glycation endproducts (AGEs) and their receptor (RAGE)
are implicated to play a role in the pathogenesis.
Purpose: We investigated the effects of candesartan, an angiotensin type II receptor blocker,
on the diabetes-induced atrial structural change.
Methods and results: Diabetes was induced in 8-week-old female Sprague—Dawley rats by
intraperitoneal injection of streptozotocin at 70mg/kg. Osmotic pumps were simultaneously
set to infuse candesartan at a subdepressor dose of 0.05mg/kg/day. Twelve weeks after the
induction of diabetes, the blood glucose and glycated hemoglobin A1c were signiﬁcantly higher
in streptozotocin-injected rats than those in control rats, and were not affected by candesartan
treatment. The atria of diabetic rats showed remarkable diffuse interstitial ﬁbrosis with more
enhanced protein expressions of RAGE and connective tissue growth factor (CTGF) compared
with control ones. The treatment with candesartan signiﬁcantly reduced CTGF expression and
effectively suppressed the development of ﬁbrotic deposition in diabetic animals.
Conclusions: Candesartan reduced CTGF expression and attenuated the ﬁbrosis in diabetic rat
atria. These results implied the protective effects of candesartan on diabetes-related atrial
arrhythmias.
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ntroduction
he association of metabolic syndrome and atrial ﬁbrillation
as attracted considerable attention [1,2]. Previous epi-
emiologic studies identiﬁed diabetes mellitus (DM) as one
f the established risk factors for the development of atrial
brillation (AF) [3—7]. Because diabetes-complicated AF is
losely related to higher risk of stroke and death [8—10], it
s now an issue of great concern [11].
For diabetes-related atrial tachyarrhythmias, the
ncreased atrial ﬁbrosis, i.e. atrial structural remodeling
y DM, is considered as a major arrhythmogenic substrate
12]. We have previously reported that advanced glycation
ndproducts (AGEs) and their receptor (receptor for AGEs:
AGE) are implicated in the pathogenesis of diabetes-
nduced atrial ﬁbrosis [13]. Hypothetically, diabetes might
romote the formation of both AGEs in circulating blood
nd RAGE in atrial tissue. AGEs could interact with RAGE to
nhance connective tissue growth factor (CTGF) expression,
esulting in atrial ﬁbrosis formation. Inhibition of AGEs
ormation has thus become one of the possible therapeutic
argets for diabetes-related AF. Although several types of
GEs inhibitors, such as aminoguanidine and OPB-9195,
ere discovered, these compounds have been withdrawn
rom clinical use due to side effects related to their char-
cteristic trapping of pyridoxal with an attendant vitamin
6 deﬁciency [14].
The angiotensin-converting enzyme inhibitors (ACEIs) and
he angiotensin II type 1 receptor blockers (ARBs) are clin-
cally available anti-hypertensive drugs with established
olerance. These drugs are basically reported to have an
nhibitory effect on AGEs formation [14—16] as well as the
apability for suppressing expression of RAGE [17,18] and
TGF [19], and therefore, we sought to test the hypothesis
hat candesartan, one of the ARBs, could suppress diabetes-
nduced atrial structural remodeling. We also investigated
he effects of candesartan on atrial expression of RAGE and
TGF.
aterials and methods
nimal model
e induced diabetes in 8-week-old female Sprague—Dawley
ats by intraperitoneal administration of streptozotocin
STZ; Wako Chemicals, Osaka, Japan) at a dose of 70mg/kg
issolved in citrate buffer. Animals which showed glucose
oncentration >22mmol/L 1 week after the injection were
ncluded in this study. Control rats were treated with cit-
ate buffer without STZ. An osmotic minipump (model 2004;
lzet, Cupertino, CA, USA) was simultaneously implanted
ubcutaneously. In the candesartan treatment group, rats
ere treated with continuous subcutaneous infusion of can-
esartan (Takeda Pharmaceutical Company, Osaka, Japan)
t a subdepressor dose of 0.05mg/kg/day for 12 weeks from
he day of STZ injection [20]. At 20 weeks of age, animals
ere killed and left atrial samples were taken for histol-
gy, Western blotting, and immunohistochemical staining.
ll animal experiments and maintenance were carried out
ccording to the ethical guidelines suggested by the Institu-
ional Animal Ethics Committee.
w
t
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lood glucose and glycated hemoglobin A1c
ssessment
amples for nonfasting blood glucose and glycated
emoglobin (Hb) A1c were taken immediately after extrac-
ion of the heart. Blood glucose was measured by a glucose
nalyzer GA04 (A&T Corporation, Yokohama, Japan), and
bA1c by a commercially available kit, Determiner HbA1c
Kyowa Medex, Tokyo, Japan).
istology
horizontal section at mid atrial level was stained with
asson trichrome to evaluate the ﬁbrotic deposition in rat
tria. Images were acquired using a digital microscope,
OOLSCOPE (Nikon, Tokyo, Japan). To quantify ﬁbrotic depo-
ition of left atrium in the digitized photos, the area of blue
ixel content was measured relative to the total tissue area
sing Photoshop CS2 software (Adobe Systems, San Jose, CA,
SA).
estern blot analysis and immunohistochemistry
otal protein extracts of 10 or 30g from the left atrial
ppendages were separated by SDS-PAGE gel electrophoresis
nd transferred to PVDF membranes (Boehringer Mannheim,
annheim, Germany). The membranes were blocked and
ncubated with primary antibodies: polyclonal goat anti-
uman RAGE antibody (Santa Cruz Biotechnology, Santa
ruz, CA, USA) and polyclonal rabbit anti-mouse CTGF anti-
ody (Abcam, Cambridge, United Kingdom). Secondary anti-
odies used were donkey anti-goat immunoglobulin G (Santa
ruz Biotechnology) and goat anti-rabbit immunoglobulin G
Cell Signaling Technology, Danvers, MA, USA). The immuno-
istochemical staining was performed in cryostat sections
8m thick) by the simple stain rat MAX-PO (MULTI) labeled
olymer system (Nichirei Biosciences, Tokyo, Japan).
tatistical analysis
he data are presented as mean± SEM. Data were compared
y analysis of variance (ANOVA) with Bonferroni’s post-test
sing Prism 4.0 for Macintosh (GraphPad Software, La Jolla,
A, USA). A two-tailed p-value <0.05 was considered statis-
ically signiﬁcant.
esults
etabolic and structural parameters of
xperimental animals
n the 20-week-old STZ-induced diabetic rats, nonfasting
lasma glucose and HbA1c levels were signiﬁcantly higher
han those in control rats (Table 1). The treatment with can-
esartan did not signiﬁcantly affect these values in diabetic
odels.
At 20 weeks of age, diabetic animals showed lower body
eight compared with controls. No signiﬁcant difference in
he heart weight/body weight index was observed between
he three groups.
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Table 1 Characteristics of experimental animals.
Control DM DM+ candesartan
Body weight (g) 295 ± 2 225 ± 13* 223 ± 19*
Heart weight (g) 1.18 ± 0.03 0.97 ± 0.10 0.95 ± 0.05
HW/BW ratio (×10−2) 0.40 ± 0.01 0.43 ± 0.03 0.43 ± 0.02
Plasma glucose (mmol/L) 9.8 ± 0.5 35.9 ± 2.1* 35.3 ± 3.0*
HbA1c (%) 3.3 ± 0.1 10.2 ± 0.6* 10.4 ± 0.4*
W, he
c
R
r
c
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s
t
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t
c
t* p < 0.05 vs. control. DM, diabetes mellitus; Hb, hemoglobin; H
Diabetes-induced atrial structural changes
Representative Masson trichrome stainings of left atrial sec-
tions are displayed in Fig. 1(A, control rats; B, diabetic
rats; C, diabetic rats with candesartan). Histologically, the
20-week-old diabetic rats atria without treatment were
characterized by enhanced ﬁbrotic depositions (Fig. 1B),
compared with control ones (Fig. 1A). The development of
these diabetes-induced structural changes was prevented by
the administration of candesartan (Fig. 1C). The quantiﬁed
area of ﬁbrosis in three groups (Fig. 1D) was 14.0± 1.1% in
the control group, 30.9± 1.7% in the diabetic group (p < 0.01
vs. control), and 20.5± 1.4% in the diabetic + candesartan
group (p < 0.01 vs. diabetic), respectively.Expression of RAGE in the atrium
The images of RAGE immunostainings are presented in
Fig. 2(A, control rats; B, diabetic rats; C, diabetic rats with
r
t
W
i
Figure 1 Histology of left atria. (A—C) Masson trichrome stainings o
Compared with control rats (A), the blue-stained ﬁbrotic deposition
candesartan treatment diminished the diabetes-induced atrial ﬁbros
in the three groups (*p < 0.01 vs. control; †p < 0.01 vs. diabetes; n = 6art weight; BW, body weight.
andesartan). As shown in these ﬁgures, the stainings for
AGE protein were greatly enhanced in the atria of diabetic
ats (Fig. 2B), while they were rarely observed in those of
ontrol rats (Fig. 2A). The quantiﬁcation by Western blot-
ing conﬁrmed the ﬁnding that the expression of RAGE was
igniﬁcantly increased in diabetic rats compared with con-
rol rats (p < 0.01), and was not suppressed by candesartan
reatment (Fig. 3).
xpression of CTGF in the atrium
ig. 4 shows representative photographs of CTGF immunos-
aining (A, control rats; B, diabetic rats; C, diabetic rats with
andesartan). CTGF proteins were abundantly expressed in
he atrium of diabetic rats (Fig. 4B) compared with control
ats (Fig. 4A). The administration of candesartan diminished
his diabetes-induced CTGF immunostaining (Fig. 4C). In the
estern blotting analysis (Fig. 5), diabetic rat atria showed
ncreased atrial CTGF immunoreactive protein compared
f left atria (A, control; B, diabetes; C, diabetes + candesartan).
s were much more abundant in the diabetic rats atria (B). The
is (C). (D) Quantiﬁed relative areas of atrial ﬁbrotic depositions
per group). DM, diabetes mellitus.
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Figure 2 Immunohistochemical stainings of left atria for RAGE (A, control; B, diabetes; C, diabetes + candesartan). The RAGE
expression indicated as brown staining was prominent in atria of diabetic rats (B) compared with those of control rats (A). The
treatment with candesartan did not modify the diabetes-induced s
endproducts.
Figure 3 Western blotting analysis for RAGE. The expression
of RAGE was signiﬁcantly increased in diabetic rats atria com-
pared with control ones. The administration of candesartan did
not affect the level of RAGE protein. *p < 0.01 vs. control, n = 6
per group. DM, diabetes mellitus; RAGE, receptor for advanced
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igure 4 Immunohistochemical staining of left atria for CTGF (A
taining indicative of CTGF expression was prominent in diabetic r
reatment with candesartan reduced the CTGF immunostaining (C).taining for RAGE (C). RAGE, receptor for advanced glycation
ith control ones (p < 0.01). The candesartan treatment sig-
iﬁcantly diminished the diabetes-induced upregulation of
TGF protein (p < 0.01).
iscussion
ajor ﬁndings
he major ﬁndings of the present study are as follows:
1) the STZ-induced diabetic rat atria showed structural
emodeling characterized by diffuse interstitial ﬁbrosis
ccompanied by increased expressions of RAGE and CTGF.
2) The subcutaneously administered candesartan, at a sub-
epressor dose, effectively suppressed the diabetes-induced
trial ﬁbrosis with reduced expression of CTGF. (3) Candesar-
an did not affect the atrial expression of RAGE.
M as a risk factor for AF
ccording to the Framingham Heart Study, DM and hyperten-
ion were risk factors for AF development after adjusting
or age and other predisposing conditions [3]. Also, other
pidemiological studies have identiﬁed DM as a strong inde-
endent risk factor for AF and atrial ﬂutter with an odds ratio
, control; B, diabetes; C, diabetes + candesartan). The brown
ats (B), while it was rarely detected in control rats (A). The
CTGF, connective tissue growth factor.
Angiotensin II type 1 receptor blocker attenuates diabetes-induc
Figure 5 Western blotting analysis for CTGF. The expres-
sion of CTGF was signiﬁcantly increased in diabetic rats atria
compared with controls. The administration of candesartan
signiﬁcantly attenuated the diabetes-induced CTGF overexpres-
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Referencession. *p < 0.01 vs. control, †p < 0.01 vs. DM, n = 6 per group. CTGF,
connective tissue growth factor.
of 1.4—2.2 [3—6]. It should be also recognized that patients
with diabetes-complicated AF are associated with poor out-
comes [8,9]. In spite of these facts, the effective and safe
treatment for this type of AF has not been established yet.
Mechanisms of diabetes-related AF
The pathophysiological mechanisms between DM and AF
were investigated initially using genetic type-2 DM model,
Goto-Kakizaki (GK) rat [12]. This diabetic GK rat presented
atrial arrhythmogenicity with disturbances in the intra-atrial
conduction. The atrial refractoriness of the GK rat was simi-
lar to that of non-diabetic rats. This diabetic rat model also
showed increased atrial ﬁbrosis. These observations imply
that atrial structural remodeling could be a major substrate
for diabetes-related atrial tachyarrhythmias.
Role of AGEs-RAGE system for ﬁbrosis development
Hyperglycemia enhances the formation of AGEs, which are
formed by the nonenzymatic reaction of glucose and other
glycating compounds with proteins [21—23]. Plasma pro-
teins modiﬁed by AGEs precursors bind to RAGE on cells
such as macrophages, vascular endothelial cells, and vascu-
lar smooth muscle cells [24,25]. This induces the production
of reactive oxygen species, and activation of nuclear factor
-B, causing multiple inﬂammatory cascades in gene expres-
sion [26—30].
RAGE expression is low during homeostasis, but is strik-
ingly enhanced in conditions including DM, uremia, and
inﬂammation [31,32]. In the previous study, we demon-
strated that RAGE expression, as well as CTGF expression,
was increased in the atria of diabetic rats [13]. The AGEs
formation inhibitor, OPB-9195 effectively attenuated CTGF
expression and suppressed the development of atrial ﬁbrosis
without improving hyperglycemia. These ﬁndings indicateded atrial structural remodeling 135
he involvement of AGEs-RAGE axis in the development of
iabetes-induced atrial structural remodeling.
nhibitory effects of ARB for AGEs-RAGE axis
iyata et al. reported that ARBs, as well as ACEIs, unlike
ifedipine, a calcium blocker, markedly inhibit in vitro
he formation of two AGEs, pentosidine and N(epsilon)-
arboxymethyllysine (CML), during incubation of diabetic
remic plasma or of BSA fortiﬁed with arabinose [14]. This
ffect is shared by all tested ACEIs and ARBs, including can-
esartan, which are more efﬁcient than aminoguanidine or
yridoxamine on an equimolar basis. Their effects are differ-
nt from aminoguanidine and OPB-9195 in that they did not
eact with pyridoxal. Another report also showed that the
ncrease of renal AGE accumulation by diabetes was attenu-
ted by both ramipril and aminoguanidine to a similar degree
16]. ARBs are also supposed to suppress the expression of
AGE and CTGF as well as AGEs formation [17—19].
In the present study, we have demonstrated that a
ubdepressor dose of candesartan could suppress diabetes-
nduced atrial ﬁbrosis with reduced expression of CTGF.
his improvement was not associated with a change in
AGE expression. Although the precise mechanisms remain
o be elucidated, these results might imply the possibility
hat the relatively small dose of candesartan could sup-
ress diabetes-induced AGEs formation in circulating blood,
eing insufﬁcient to eliminate the atrial overexpression of
AGE. The reduced CTGF expression by candesartan might
e derived via decreased AGEs interaction with RAGE and/or
rom a direct effect of the drug.
imitations
ome limitations are included in the present study. First,
t is unknown if the present results could apply to other
odels of diabetes. Second, although we administered can-
esartan at a subdepressor dose based on a previous report
20], we could not exclude the concomitant changes of
he left atrial pressure induced by diabetes or candesar-
an treatment, which may have a potential impact on atrial
orphological changes. Finally, we could not deny that the
resent protective effect of candesartan is derived from
GEs-RAGE independent pathways because ARBs have mul-
iple pleiotropic effects. Further research using a RAGE
nockout model would be required.
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